Author:
Dax Oliver City University of New York, Graduate Center, 365 Fifth Avenue, New York, NY 10016, USA

Search for other papers by Dax Oliver in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0009-0001-7963-1870
Open access

Abstract

I propose that positive mood should not be among the criteria for determining when or if psychedelic experiences are mystical. My primary reasons are: 1) unlike rare proposed mystical criteria such as feelings of self-dissolution and time-transcendence, positive mood does not clearly separate mystical experiences from other emotionally powerful experiences like being in love; 2) other proposed mystical criteria can occur with non-positive moods; and 3) it is not true that framing all mystical experiences with only positive mood is more pragmatic.

Abstract

I propose that positive mood should not be among the criteria for determining when or if psychedelic experiences are mystical. My primary reasons are: 1) unlike rare proposed mystical criteria such as feelings of self-dissolution and time-transcendence, positive mood does not clearly separate mystical experiences from other emotionally powerful experiences like being in love; 2) other proposed mystical criteria can occur with non-positive moods; and 3) it is not true that framing all mystical experiences with only positive mood is more pragmatic.

Introduction

Many psychedelic researchers currently consider positive mood to be among the indicators that a psychedelic experience is “mystical,” largely due to the influence of philosopher Walter Stace (Letheby, 2021, p. 25; Stace, 1961, p. 68). However, I propose that positive mood should not be among the criteria for determining mysticality of psychedelic experiences. My primary reasons are: 1) unlike rare proposed mystical criteria such as feelings of self-dissolution and time-transcendence, positive mood does not clearly separate mystical experiences from other emotionally powerful experiences like being in love; 2) other proposed mystical criteria can occur with non-positive moods; and 3) it is not true that framing all mystical experiences with only positive mood is more pragmatic.

Although the term “mystical” has historically sometimes been associated with supernatural or spiritual beliefs, reported feelings of mysticality among psychedelic research participants can be studied without making ontological claims about those feelings (McCulloch et al., 2022, p. 13). For example, versions of the Mystical Experience Questionnaire, Hood's Mysticism Scale, and other surveys have sometimes been used by researchers to assess the mysticality of psychedelic experiences (Griffiths, Richards, McCann, & Jesse, 2006, p. 5). These questionnaires ask people if their experiences included mystical-type feelings, some of which might be internal unity (merging of self with a larger reality), transcendence of time and space, or deeply felt positive mood (Griffiths et al., 2006, p. 5).

Positive mood (even deeply felt) is too common to differentiate experiences as mystical

The goal of the above surveys is to clearly delineate mystical experiences from other types of experiences (Barrett, Johnson, & Griffiths, 2015, p. 2). However, I think deeply felt positive mood would contribute little to this goal even if it reliably accompanied other proposed mystical criteria. If you are feeling deep positive mood and that your self has dissolved or you have transcended time—I think it is reasonable to say that the self-dissolution and time-transcendence are doing the heavy lifting for the rarity of this particular experience. Some might counterargue that mystical positive mood is especially strong, but this could also apply to the positive mood of being in love or bonding with a newborn baby, which are very widespread experiences (luckily for our species).

One objection here might be that if positive mood reliably accompanies mystical experiences, then it would still be accurate to include it as a criterion, no matter how often it also occurs in non-mystical experiences. I will discuss in more depth below why I do not believe positive mood reliably accompanies other proposed criteria of mystical experiences. However, even if we lived in an alternate reality where all currently known mystical experiences had positive mood, I would lean toward using Occam's Razor and being as parsimonious as possible with our criteria. If positive mood is not necessary to distinguish mystical experiences from other experiences, then including it in the process of determination might blind researchers to other mystical experiences of various moods.

Other proposed mystical criteria can occur with non-positive moods

There are many reports of people experiencing at least some mystical criteria while also feeling overall non-positive emotions. Even if these experiences are less frequent than ones with overall positive emotions, they still seem to occur. For example, William James described some mystical experiences as feeling so negative that they could be called “diabolical” (James, 2009, p. 323). Michael Pollan described one of his ineffable noetic experiences with the psychedelic DMT (N,N-dimethyltryptamine) as “pure and terrible sensation” (Pollan, 2018, p. 277).

Obviously, most psychedelic researchers are highly aware of these non-positive experiences (Carbonaro et al., 2016, p. 2). Yet many researchers (as discussed above) persist in using positive mood as one of the markers of mystical experiences. Considering the contrary evidence, this seems inconsistent.

A possible objection here might be that perhaps a different term should be used for what I am calling non-positive mystical experiences. In this way, we could still acknowledge the power of these experiences, while reserving “mystical” for positive experiences. Maybe there could also be a separate umbrella term for experiences regardless of mood (e.g. “transcendent”), with subcategories of “mystical” and “[terms for non-positive experiences].”

However, I think this objection still ignores the earlier problem of positive mood having lower ontological importance compared to other proposed mystical criteria. Positive mood, even very deep positive mood, is a relatively common human experience compared to mystical criteria such as feelings of self-dissolution and time-transcendence. “Mystical” is a term with a long history and great linguistic weight (Jones, 2022). I do not think it is prudent to use a relatively common criterion to determine which experiences of self-dissolution or time-transcendence earn the right to be called “mystical” as opposed to terms with less linguistic weight.

Pragmatism is not a justifiable reason for including positive mood

Some dissenters might ask if there are pragmatic benefits to reframing all mystical experiences as positive, regardless of how the experiences felt when they occurred. There are reports of people eventually reframing initially non-positive psychedelic experiences as positive (Dyck & Elcock, 2020, p. 286; Carbonaro et al., 2016, p. 10). Perhaps my focus on the occasional non-positivity of psychedelic mystical experiences could be myopic or even psychologically damaging.

I agree that experiences which feel negative in the moment (whether psychedelic or not) can sometimes eventually lead to positive changes in people's lives. However, the reverse is also true. It is an understatement to note that short-term positive feelings can sometimes lead to negative long-term changes in people's lives (e.g. romantic crushes turning into abusive marriages or happy drunken confidence leading to fatal accidents). Therefore, it seems at least possible that some psychedelic insights which feel positive in the moment should actually be reframed as potentially having negative consequences. Including positive mood in the criteria for determining mysticality might then be the less pragmatic option, since it could discourage this other type of helpful re-evaluation.

Even if we were to take a very large leap and assume that all psychedelic experiences should be framed positively, it seems a fundamental mistake to thus reclassify non-positive experiences themselves as positive. Experiencing cancer or the deaths of loved ones might also sometimes lead to positive changes in people's lives, but it seems extreme to claim that these experiences are actually inherently positive.

There are, admittedly, some people who do go this far. Pope Francis has said that even the darkest suffering is a “gift of tears” (Fincher, 2013). Still, I think even most of these dissenters would agree that during the actual occurrences of horrendous life experiences, the overall mood can at least sometimes feel negative, no matter how the experiences are viewed later. It seems odd to withhold a designation of “mystical” from experiences until some unknown future time when they can finally be remembered positively. Thus, I think in regard to mystical experiences themselves, my argument to remove positive mood from the determining criteria does not seem affected by the objection from pragmatism.

Conclusion

To reiterate, 1) unlike rare proposed mystical criteria such as feelings of self-dissolution and time-transcendence, positive mood does not clearly separate mystical experiences from other emotionally powerful experiences like being in love; 2) other proposed mystical criteria can occur with non-positive moods; and 3) it is not true that framing all mystical experiences with only positive mood is more pragmatic.

I hope this paper sways at least some psychedelic researchers (as well as researchers of non-psychedelic feelings of mysticality) to recognize the existence of experiences that are both mystical and not positive. Positive mood has shown such potential as a data point in psychedelic research that I suspect it has overshadowed research into the criteria which truly make some experiences mystical. Going forward, I think it would be advisable to not conflate the effects of positive mood with the effects of mystical experiences.

References

  • Barrett, F., Johnson, M., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 11831190.

    • Search Google Scholar
    • Export Citation
  • Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 12681278 (pdf 1-22).

    • Search Google Scholar
    • Export Citation
  • Dyck, E., & Elcock, C. (2020). Reframing bummer trips: Scientific and cultural explanations to adverse reactions to psychedelic drug use. The Social History of Alcohol and Drugs, 34(2), 271296.

    • Search Google Scholar
    • Export Citation
  • Fincher, M. (2013, September 16). Pope Francis extols ‘gift of tears’. National Catholic Reporter. Retrieved from https://www.ncronline.org/blogs/francis-chronicles/pope-francis-extols-gift-tears. Accessed 2023, April 14.

    • Search Google Scholar
    • Export Citation
  • Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187, 268283 (original investigation 1–16).

    • Search Google Scholar
    • Export Citation
  • James, W. (2009). The varieties of religious experience: A study in human nature. Adelaide, Australia: University of Adelaide Library.

  • Jones, R. (2022). Mysticism. Stanford Encyclopedia of Philosophy. https://plato.stanford.edu/entries/mysticism/.

  • Letheby, C. (2021). Philosophy of psychedelics. Oxford, United Kingdom: Oxford University Press.

  • McCulloch, D. E-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., et al. (2022). Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.841648.

    • Search Google Scholar
    • Export Citation
  • Pollan, M. (2018). How to change your mind. New York, NY, USA: Penguin.

  • Stace, W. (1961). Mysticism and philosophy. London, United Kingdom: Macmillan.

  • Barrett, F., Johnson, M., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 11831190.

    • Search Google Scholar
    • Export Citation
  • Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 12681278 (pdf 1-22).

    • Search Google Scholar
    • Export Citation
  • Dyck, E., & Elcock, C. (2020). Reframing bummer trips: Scientific and cultural explanations to adverse reactions to psychedelic drug use. The Social History of Alcohol and Drugs, 34(2), 271296.

    • Search Google Scholar
    • Export Citation
  • Fincher, M. (2013, September 16). Pope Francis extols ‘gift of tears’. National Catholic Reporter. Retrieved from https://www.ncronline.org/blogs/francis-chronicles/pope-francis-extols-gift-tears. Accessed 2023, April 14.

    • Search Google Scholar
    • Export Citation
  • Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187, 268283 (original investigation 1–16).

    • Search Google Scholar
    • Export Citation
  • James, W. (2009). The varieties of religious experience: A study in human nature. Adelaide, Australia: University of Adelaide Library.

  • Jones, R. (2022). Mysticism. Stanford Encyclopedia of Philosophy. https://plato.stanford.edu/entries/mysticism/.

  • Letheby, C. (2021). Philosophy of psychedelics. Oxford, United Kingdom: Oxford University Press.

  • McCulloch, D. E-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., et al. (2022). Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.841648.

    • Search Google Scholar
    • Export Citation
  • Pollan, M. (2018). How to change your mind. New York, NY, USA: Penguin.

  • Stace, W. (1961). Mysticism and philosophy. London, United Kingdom: Macmillan.

  • Collapse
  • Expand
The author instruction is available in PDF.
Please, download the file from HERE

Book Review Guidelines are available from HERE.

 

Editor-in-Chief:

Attila Szabo - University of Oslo

E-mail address: attilasci@gmail.com

Associate Editors:

  • Alan K. Davis - The Ohio State University & Johns Hopkins University, USA
  • Zsolt Demetrovics - Eötvös Loránd University, Budapest, Hungary
  • Ede Frecska, founding Editor-in-Chief - University of Debrecen, Debrecen, Hungary
  • David Luke - University of Greenwich, London, UK
  • Dennis J. McKenna- Heffter Research Institute, St. Paul, USA
  • Jeremy Narby - Swiss NGO Nouvelle Planète, Lausanne, Switzerland
  • Stephen Szára - Retired from National Institute on Drug Abuse, Bethesda, USA
  • Enzo Tagliazucchi - Latin American Brain Health Institute, Santiago, Chile, and University of Buenos Aires, Argentina
  • Michael Winkelman - Retired from Arizona State University, Tempe, USA 

Book Reviews Editor:

Michael Winkelman - Retired from Arizona State University, Tempe, USA

Editorial Board

  • Gábor Andrássy - University of Debrecen, Debrecen, Hungary
  • Tiago Arruda-Sanchez - Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Paulo Barbosa - State University of Santa Cruz, Bahia, Brazil
  • Michael Bogenschutz - New York University School of Medicine, New York, NY, USA
  • Petra Bokor - University of Pécs, Pécs, Hungary
  • Jose Bouso - Autonomous University of Madrid, Madrid, Spain
  • Zoltán Brys - Multidisciplinary Soc. for the Research of Psychedelics, Budapest, Hungary
  • Susana Bustos - California Institute of Integral Studies San Francisco, USA
  • Robin Carhart-Harris - Imperial College, London, UK
  • Per Carlbring - Stockholm University, Sweden
  • Valerie Curran - University College London, London, UK
  • Alicia Danforth - Harbor-UCLA Medical Center, Los Angeles, USA
  • Rick Doblin - Boston, USA
  • Rafael G. dos Santos - University of Sao Paulo, Sao Paulo, Brazil
  • Genis Ona Esteve - Rovira i Virgili University, Spain
  • Silvia Fernandez-Campos
  • Zsófia Földvári - Oslo University Hospital, Oslo, Norway
  • Andrew Gallimore - University of Cambridge, Cambridge, UK
  • Neal Goldsmith - private practice, New York, NY, USA
  • Charles Grob - Harbor-UCLA Medical Center, Los Angeles, CA, USA
  • Stanislav Grof - California Institute of Integral Studies, San Francisco, CA, USA
  • Karen Grue - private practice, Copenhagen, Denmark
  • Jiri Horacek - Charles University, Prague, Czech Republic
  • Lajos Horváth - University of Debrecen, Debrecen, Hungary
  • Robert Jesse - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Matthew Johnson - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • István Kelemen - University of Debrecen, Debrecen, Hungary
  • Eli Kolp - Kolp Institute New, Port Richey, FL, USA
  • Stanley Krippner - Saybrook University, Oakland, CA, USA
  • Evgeny Krupitsky - St. Petersburg State Pavlov Medical University, St. Petersburg, Russia
  • Rafael Lancelotta - Innate Path, Lakewood, CO, USA
  • Anja Loizaga-Velder - National Autonomous University of Mexico, Mexico City, Mexico
  • Luis Luna - Wasiwaska Research Center, Florianópolis, Brazil
  • Katherine MacClean - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Deborah Mash - University of Miami School of Medicine, Miami, USA
  • Friedericke Meckel - private practice, Zurich, Switzerland
  • Ralph Metzner - California Institute of Integral Studies, San Francisco, CA, USA
  • Michael Mithoefer - private practice, Charleston, SC, USA
  • Levente Móró - University of Turku, Turku, Finland
  • David Nichols - Purdue University, West Lafayette, IN, USA
  • David Nutt - Imperial College, London, UK
  • Torsten Passie - Hannover Medical School, Hannover, Germany
  • Janis Phelps - California Institute of Integral Studies, San Francisco, CA, USA
  • József Rácz - Semmelweis University, Budapest, Hungary
  • Christian Rätsch - University of California, Los Angeles, Los Angeles, CA, USA
  • Jordi Riba - Sant Pau Institute of Biomedical Research, Barcelona, Spain
  • Sidarta Ribeiro - Federal University of Rio Grande do Norte, Natal, Brazil
  • William Richards - Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Stephen Ross - New York University, New York, NY, USA
  • Brian Rush - University of Toronto, Toronto, Canada
  • Eduardo Schenberg - Federal University of São Paulo, São Paulo, Brazil
  • Ben Sessa - Cardiff University School of Medicine, Cardiff, UK
  • Lowan H. Stewart - Santa Fe Ketamine Clinic, NM, USA (Medical Director)
  • Rebecca Stone - Emory University, Atlanta, GA, USA
  • Rick Strassman - University of New Mexico School of Medicine, Albuquerque, NM, USA
  • Attila Szabó - University of Oslo, Oslo, Norway
  • Csaba Szummer - Károli Gáspár University of the Reformed Church, Budapest, Hungary
  • Manuel Torres - Florida International University, Miami, FL, USA
  • Luís Fernando Tófoli - University of Campinas, Campinas, Brazil State
  • Malin Uthaug - Maastricht University, Maastricht, The Netherlands
  • Julian Vayne - Norwich, UK
  • Nikki Wyrd - Norwich, UK

Attila Szabo
University of Oslo

E-mail address: attilasci@gmail.com

Indexing and Abstracting Services:

  • Web of Science ESCI
  • Biological Abstracts
  • BIOSIS Previews
  • APA PsycInfo
  • DOAJ
  • Scopus
  • CABELLS Journalytics

2022  
Web of Science  
Total Cites
WoS
226
Journal Impact Factor 4.5
Rank by Impact Factor

n/a

Impact Factor
without
Journal Self Cites
4.1
5 Year
Impact Factor
n/a
Journal Citation Indicator 0.97
Rank by Journal Citation Indicator

Pharmacology & Pharmacy 91/362
Psychiatry 69/264

Scimago  
Scimago
H-index
5
Scimago
Journal Rank
0.416
Scimago Quartile Score

Anthropology Q1
Biological Psychiatry Q4
Clinical Psychology Q3
Health (social science) Q3
Pharmacology Q3
Psychiatry and Mental Health Q3
Social Psychology Q3

Scopus  
Scopus
Cite Score
4.2
Scopus
CIte Score Rank
Anthropology 31/468 (93rd PCTL)
Health (social science) 78/344 (77th PCTL)
Social Psychology 96/292 (70th PCTL)
Clinical Psychology 96/292 (67th PCTL)
Psychiatry and Mental Health 219/531 (58th PCTL)
Pharmacology (medical) 115/260 (55th PCTL)
Biological Psychiatry 30/47 (37th PCTL)
Scopus
SNIP
0.627

2021  
Web of Science  
Total Cites
WoS
not indexed
Journal Impact Factor not indexed
Rank by Impact Factor

not indexed

Impact Factor
without
Journal Self Cites
not indexed
5 Year
Impact Factor
not indexed
Journal Citation Indicator not indexed
Rank by Journal Citation Indicator

not indexed

Scimago  
Scimago
H-index
2
Scimago
Journal Rank
not yet available
Scimago Quartile Score Anthropology (Q3)
Biological Psychiatry (Q4)
Clinical Psychology (Q4)
Health (social science) (Q4)
Pharmacology (medical) (Q4)
Psychiatry and Mental Health (Q4)
Social Psychology (Q4)
Scopus  
Scopus
Cite Score
0,9
Scopus
CIte Score Rank
Anthropology 186/443 (Q2)
Health (social science) 234/323 (Q3)
Clinical Psychology 213/292 (Q3)
Pharmacology (medical) 190/255 (Q3)
Psychiatry and Mental Health 419/529 (Q4)
Social Psychology 243/296 (Q4)
Biological Psychiatry 38/43 (Q4)
Scopus
SNIP
0,381

2020  
CrossRef Documents 8
WoS Cites 37
WoS H-index 4
Days from submission to acceptance 95
Days from acceptance to publication 75
Acceptance Rate 41%

2019  
WoS
Cites
11
CrossRef
Documents
35
Acceptance
Rate
77%

 

Journal of Psychedelic Studies
Publication Model Gold Open Access
Submission Fee none
Article Processing Charge none
Subscription Information Gold Open Access

Journal of Psychedelic Studies
Language English
Size A4
Year of
Foundation
2016
Volumes
per Year
1
Issues
per Year
3
Founder Akadémiai Kiadó
Debreceni Egyetem
Eötvös Loránd Tudományegyetem
Károli Gáspár Református Egyetem
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
H-4032 Debrecen, Hungary Egyetem tér 1.
H-1053 Budapest, Hungary Egyetem tér 1-3.
H-1091 Budapest, Hungary Kálvin tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2559-9283 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2023 0 0 0
Jul 2023 0 0 0
Aug 2023 0 0 0
Sep 2023 0 3709 173
Oct 2023 0 5556 38
Nov 2023 0 5526 27
Dec 2023 0 1829 21